Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 8/2014

01-08-2014 | Gynecologic Oncology

Comparative Patient-Centered Outcomes (Health State and Adverse Sexual Symptoms) Between Adjuvant Brachytherapy Versus No Adjuvant Brachytherapy in Early Stage Endometrial Cancer

Authors: Shari Damast, MD, Kaled Alektiar, MD, Anne Eaton, MS, Naamit Kurshan Gerber, MD, Shari Goldfarb, MD, Sujata Patil, PhD, Rachel Jia, MS, Mario Leitao, MD, Jeanne Carter, PhD, Ethan Basch, MD, MSc

Published in: Annals of Surgical Oncology | Issue 8/2014

Login to get access

Abstract

Purpose

To determine a relationship between sexual functioning and health state among survivors of stage I endometrial cancer, and to examine whether adjuvant intravaginal radiotherapy (IVRT) affects these measures compared to hysterectomy alone.

Methods

Two hundred five survivors (>1 year from surgery) completed questionnaires containing the EuroQol (EQ5D) and the Female Sexual Function Index (FSFI). A total of 136 (66.3 %) underwent surgery alone, and 69 (33.7 %) received IVRT. Pearson correlation was used to correlate FSFI and EQ5D–Health State scores. Multivariable regression was performed to measure the impact of IVRT on sexual functioning and health state.

Results

A majority of patients (80 %) met criteria for sexual dysfunction by FSFI < 26.5. A significant correlation was detected between FSFI and EQ5D scores (Pearson correlation = 0.21, p = 0.003). Compared to the IVRT group, the surgery group was younger (p = 0.001) and trended toward more frequent use of minimally invasive surgery versus laparotomy (p = 0.08). Otherwise, the two groups were well balanced with respect to demographics, comorbidities, and baseline sexual activity. Controlling for age and surgery type, IVRT was not associated with poorer health state or sexual function. Receipt of laparotomy was associated with both poorer health state and sexual function (p = 0.0156 and p = 0.0247, respectively).

Conclusions

Sexual functioning was generally poor among endometrial cancer survivors; however, those with improved FSFI scores tended to have superior health states. IVRT was not a significant risk factor; however, receipt of laparotomy appeared to be associated with poorer sexual functioning and health state.
Appendix
Available only for authorised users
Literature
1.
Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220–41.PubMedCrossRef
2.
Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;355:1404–11.PubMedCrossRef
3.
Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744–51.PubMedCrossRef
4.
Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375:816–23.PubMedCrossRef
5.
Nout RA, Putter H, Jurgenliemk-Schulz IM, et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol. 2009;27:3547–56.PubMedCrossRef
6.
Nout RA, Putter H, Jurgenliemk-Schulz IM, et al. Five-year quality of life of endometrial cancer patients treated in the randomized PORTEC-2 trial and comparison with norm data. Eur J Cancer. 2012;48:1638–48.PubMedCrossRef
7.
Sorbe B, Nordstrom B, Maenpaa J, et al. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer. A controlled randomized study. Int J Gynecol Cancer. 2009;19:873–8.PubMedCrossRef
8.
9.
Pitkin RM, VanVoorhis LW. Post-irradiation vaginitis. An evaluation of prophylaxis with topical estrogen. Radiology. 1971;99:417–21.PubMed
10.
Bentzen SM. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer. 2006;6:702–13.PubMedCrossRef
11.
Decruze SB, Guthrie D, Magnani R. Prevention of vaginal stenosis in patients following vaginal brachytherapy. Clin Oncol. 1999;11:46–8.CrossRef
12.
Bruner DW, Lanciano R, Keegan M, Corn B, Martin E, Hanks GE. Vaginal stenosis and sexual function following intracavitary radiation for the treatment of cervical and endometrial carcinoma. Int J Radiat Oncol Biol Phys. 1993;27:825–30.PubMedCrossRef
13.
Onujiogu N, Johnson T, Seo S, et al. Survivors of endometrial cancer: who is at risk for sexual dysfunction? Gynecol Oncol. 2011;123:356–9.PubMedCrossRef
14.
Becker M, Malafy T, Bossart M, Henne K, Gitsch G, Denschlag D. Quality of life and sexual functioning in endometrial cancer survivors. Gynecol Oncol. 2011;121:169–73.PubMedCrossRef
15.
Quick AM, Seamon LG, Abdel-Rasoul M, Salani R, Martin D. Sexual function after intracavitary vaginal brachytherapy for early-stage endometrial cancer. Int J Gynecol Cancer. 2012;22:703–8.PubMedCentralPubMedCrossRef
16.
The EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.CrossRef
17.
Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26:191–208.PubMedCrossRef
18.
Wiegel M, Meston C, Rosen R. The Female Sexual Function Index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31:1–20.PubMedCrossRef
19.
Goldfarb S, Dickler M, Patil S, et al. Sexual dysfunction in women with breast cancer: prevalence and severity (abstract 30). J Sex Med. 2011;8(Suppl 2):66.
20.
Nout RA, van de Poll-Franse LV, Lybeert ML, et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the Post Operative Radiation Therapy in Endometrial Carcinoma 1 (PORTEC-1) trial. J Clin Oncol. 2011;29:1692–700.PubMedCrossRef
21.
Kornblith AB, Huang HQ, Walker JL, et al. Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27:5337–42.PubMedCentralPubMedCrossRef
22.
Carter J, Huang H, Chase DM, et al. Sexual function of patients with endometrial cancer enrolled in the Gynecologic Oncology Group LAP2 study. Int J Gynecol Cancer. 2012;22:1624–33.PubMedCentralPubMedCrossRef
23.
Verit FF, Verit A, Billurcu N. Low sexual function and its associated risk factors in pre- and postmenopausal women without clinically significant depression. Maturitas. 2009;64:38–42.PubMedCrossRef
24.
Olarinoye J, Olarinoye A. Determinants of sexual function among women with type 2 diabetes in a Nigerian population. J Sex Med. 2008;5:878–86.PubMedCrossRef
25.
Bayser RE, Li Y, Carter J. Psychometric validation of the Female Sexual Function Index (FSFI) in cancer survivors. Cancer. 2012;118:4606–18.CrossRef
Metadata
Title
Comparative Patient-Centered Outcomes (Health State and Adverse Sexual Symptoms) Between Adjuvant Brachytherapy Versus No Adjuvant Brachytherapy in Early Stage Endometrial Cancer
Authors
Shari Damast, MD
Kaled Alektiar, MD
Anne Eaton, MS
Naamit Kurshan Gerber, MD
Shari Goldfarb, MD
Sujata Patil, PhD
Rachel Jia, MS
Mario Leitao, MD
Jeanne Carter, PhD
Ethan Basch, MD, MSc
Publication date
01-08-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 8/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3562-4

Other articles of this Issue 8/2014

Annals of Surgical Oncology 8/2014 Go to the issue

Gastrointestinal Oncology

Laparoscopic Intragastric Surgery for Early Gastric Cancer and Gastrointestinal Stromal Tumors

Gastrointestinal Oncology

Prognostic Significance of Non-curative Gastrectomy for Incurable Gastric Carcinoma

Gynecologic Oncology

The Role of Omentectomy and Random Peritoneal Biopsies as Part of Comprehensive Surgical Staging in Apparent Early-Stage Epithelial Ovarian Cancer

Gastrointestinal Oncology

Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: A Feasible and Effective Option for Colorectal Cancer Patients After Emergency Surgery in the Presence of Peritoneal Carcinomatosis

Bone and Soft Tissue Sarcomas

Analysis of Prognostic Factors Impacting Oncologic Outcomes After Neoadjuvant Tyrosine Kinase Inhibitor Therapy for Gastrointestinal Stromal Tumors

Healthcare Policy and Outcomes

Quality of Colorectal Cancer Care Among Veterans: A 10-Year Retrospective Cohort